Brown Advisory
IOVA icon

Brown Advisory’s Iovance Biotherapeutics IOVA Stock Holding History

Brown Advisory’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-757,621
Closed -$24M – 1104
2021
Q1 		$24M Buy
757,621
+20,991
+3% +$870K 0.04% 260
2020
Q4 		$34.2M Buy
736,630
+14,998
+2% +$595K 0.06% 209
2020
Q3 		$23.8M Buy
721,632
+20,155
+3% +$618K 0.05% 221
2020
Q2 		$19.3M Buy
701,477
+33,579
+5% +$1.1M 0.04% 229
2020
Q1 		$20M Buy
667,898
+3,046
+0.5% +$80.7K 0.06% 210
2019
Q4 		$18.4M Buy
664,852
+32,881
+5% +$748K 0.05% 259
2019
Q3 		$11.5M Buy
+631,971
New +$14M 0.03% 302

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Brown Advisory's IOVA Position: Q2 2021 in Review

Brown Advisory sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 757,621 shares — an estimated $24M sold.

Brown Advisory first reported a position in IOVA in Q3 2019 and held it in 7 quarters. The position peaked at $34.2M in Q4 2020. 234 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

  • Brown Advisory reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Brown Advisory sold 757,621 Iovance Biotherapeutics shares in Q2 2021, an estimated $24M.
  • Brown Advisory first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 7 quarters.
  • Brown Advisory's Iovance Biotherapeutics position peaked at $34.2M in Q4 2020.
  • 234 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Brown Advisory's 13F filing for Q2 2021, filed 29 Jul 2021.